Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR1020 plus docetaxel vs docetaxel in second-line advanced non-squamous NSCLC
CTR20150698Phase 3Suspended
- Sponsor
- Hengrui Therapeutics
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of famitinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Hengrui Therapeutics. Started May 2016; status: suspended.
02
Drugs
famitinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20150698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150698.